Monday's session saw a range of sizable moves across the market-cap spectrum, with individual company news and corporate actions driving sharp percentage changes in share prices. Semiconductor-related names registered some of the largest declines among mega-cap stocks, while other groups saw mixed performance tied to deal announcements and clinical trial outcomes.
Mega-cap movers
- Micron Technology (MU): -6.93%
- Intel Corp (INTC): -5.86%
- Applied Materials (AMAT): +5.91%
Large-cap movers
- New Providence Acquisition Corp N (ASTS): +10.94%
- Rocket Lab to acquire Iridium for $8 billion in cash and stock; Vector Acquisition (RKLB): +9.13%
- Comcast plans to spin off NBCUniversal and Sky; Comcast Corp New (CMCSA): +8.22%
- Good Works Acquisition (CIFR): -5.08%
Mid-cap movers
- Colonnade Acquisition (OUST): +17.69%
- Galena Biopharma (SLS): +13.88%
- Cree Inc. (WOLF): -6.66%
- SNXX (SNXX): -14.27%
Small-cap movers
- B.Riley upgrades FuelCell Energy stock rating on data center deal; FuelCell Energy (FCEL): +18.83%
- Quidel Corp (QDEL): +36.26%
- Evommune's EVO756 fails phase 2b trial in chronic urticaria; Evommune (EVMN): -31.57%
- Larimar submits first module of rolling BLA for nomlabofusp; Zafgen Inc (LRMR): -18.17%
The day's largest mega-cap declines were concentrated in semiconductor-related issuers, with Micron and Intel both posting losses near 6% to 7%. Applied Materials bucked that trend among the largest companies, advancing nearly 6%.
Among large-cap issues, several names moved on transaction-related news. New Providence Acquisition Corp N rose by double digits, while Vector Acquisition shares rallied after an announced deal in which Rocket Lab will purchase Iridium for $8 billion in cash and stock. Comcast shares climbed on plans to separate NBCUniversal and Sky from the company. Not all large-cap companies gained; Good Works Acquisition slid over 5%.
Mid-cap activity included a strong gain for Colonnade Acquisition and a double-digit rise for Galena Biopharma. Several mid-cap names fell, with SNXX down more than 14% and Cree off roughly 6.7%.
Small-cap moves were particularly volatile. FuelCell Energy jumped following a positive analyst upgrade tied to a data center deal. Quidel posted a large single-day gain, while Evommune tumbled after its EVO756 program failed a phase 2b trial in chronic urticaria. Zafgen moved lower after submitting the first module of a rolling biologics license application for nomlabofusp; the stock was down more than 18%.
These price swings reflect a mix of sector-specific catalysts - deal announcements, clinical trial results and corporate strategy shifts - that affected investor sentiment across multiple market-cap tiers.